In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
ApexOnco Front Page
Recent articles
No fewer than 14 dual-payload ADCs will be discussed.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.